SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS
Delisted
SYRS was delisted on the 19th of March, 2025.
53 hedge funds and large institutions have $60.1M invested in Syros Pharmaceuticals, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
48% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 29
Holders
53
Holding in Top 10
1
Calls
$1.98M
Puts
$94K
Top Buyers
| 1 | +$6.85M | |
| 2 | +$5.8M | |
| 3 | +$4.51M | |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$4.45M |
| 5 |
ABG
Ally Bridge Group
New York
|
+$3.43M |
Top Sellers
| 1 | -$481K | |
| 2 | -$259K | |
| 3 | -$234K | |
| 4 |
Millennium Management
New York
|
-$172K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$93K |